Phase 3 trial of libtayo® (cemiplimab-rwlc) combined with chemotherapy stopped early due to significant improvement in overall survival in patients with first-line advanced non-small cell lung cancer

Tarrytown, n.y. and paris, aug. 5, 2021 /prnewswire/ -- libtayo combined with chemotherapy increased median overall survival from 13 to 22 months, leading to a 29% reduction in the risk of death trial enrolled patients with locally advanced and metastatic disease with squamous or non-squamous histology, across all pd-l1 expression levels libtayo has now demonstrated improved overall survival as a monotherapy or in combination with chemotherapy in first-line advanced non-small cell lung cancer regeneron pharmaceuticals, inc. (nasdaq: regn) and sanofi today announced the phase 3 trial of pd-1 inhibitor libtayo in combination with platinum-doublet chemotherapy was stopped early after meeting its overall survival (os) primary endpoint in patients with advanced non-small cell lung cancer (nsclc).
REGN Ratings Summary
REGN Quant Ranking